119 related articles for article (PubMed ID: 21457469)
1. Current state of practice regarding testosterone supplementation therapy in men with prostate cancer.
Kovac JR; Pan MM; Lipshultz LI; Lamb DJ
Steroids; 2014 Nov; 89():27-32. PubMed ID: 25072793
[TBL] [Abstract][Full Text] [Related]
2. Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations.
Morgentaler A; Conners WP
Asian J Androl; 2015; 17(2):206-11. PubMed ID: 25652633
[TBL] [Abstract][Full Text] [Related]
3. Erythrocytosis Following Testosterone Therapy.
Ohlander SJ; Varghese B; Pastuszak AW
Sex Med Rev; 2018 Jan; 6(1):77-85. PubMed ID: 28526632
[TBL] [Abstract][Full Text] [Related]
4. Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases.
Wang K; Chen X; Bird VY; Gerke TA; Manini TM; Prosperi M
Int J Cancer; 2017 Nov; 141(9):1783-1793. PubMed ID: 28699177
[TBL] [Abstract][Full Text] [Related]
5. Alcohol and Prostate Cancer: Time to Draw Conclusions.
Macke AJ; Petrosyan A
Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327568
[TBL] [Abstract][Full Text] [Related]
6. Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events.
Clavell-Hernández J; Wang R
World J Mens Health; 2018 May; 36(2):92-102. PubMed ID: 29706034
[TBL] [Abstract][Full Text] [Related]
7. The Role of Testosterone Therapy in the Setting of Prostate Cancer.
Rodriguez KM; Pastuszak AW; Khera M
Curr Urol Rep; 2018 Jun; 19(8):67. PubMed ID: 29961247
[TBL] [Abstract][Full Text] [Related]
8. Safety of testosterone therapy in men with prostate cancer.
Morgentaler A; Caliber M
Expert Opin Drug Saf; 2019 Nov; 18(11):1065-1076. PubMed ID: 31495240
[No Abstract] [Full Text] [Related]
9. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.
Solomon ZJ; Mirabal JR; Mazur DJ; Kohn TP; Lipshultz LI; Pastuszak AW
Sex Med Rev; 2019 Jan; 7(1):84-94. PubMed ID: 30503797
[TBL] [Abstract][Full Text] [Related]
10. Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pAR
Gravina GL; Marampon F; Sanità P; Festuccia C; Forcella C; Scarsella L; Jitariuc A; Vetuschi A; Sferra R; Colapietro A; Carosa E; Dolci S; Lenzi A; Jannini EA
Oncotarget; 2017 Dec; 8(69):113792-113806. PubMed ID: 29371946
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effect of deoxypodophyllotoxin induces apoptosis of human prostate cancer cells.
Hu S; Zhou Q; Wu WR; Duan YX; Gao ZY; Li YW; Lu Q
Oncol Lett; 2016 Oct; 12(4):2918-2923. PubMed ID: 27698880
[TBL] [Abstract][Full Text] [Related]
12. Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapists.
Gravina GL; Di Sante S; Limoncin E; Mollaioli D; Ciocca G; Carosa E; Sanità P; Di Cesare E; Lenzi A; Jannini EA
Transl Androl Urol; 2015 Apr; 4(2):139-47. PubMed ID: 26816820
[TBL] [Abstract][Full Text] [Related]
13. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis.
Esposito K; Chiodini P; Capuano A; Bellastella G; Maiorino MI; Parretta E; Lenzi A; Giugliano D
J Endocrinol Invest; 2013 Feb; 36(2):132-9. PubMed ID: 23481613
[TBL] [Abstract][Full Text] [Related]
14. Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation.
Aversa A; Francomano D; Lenzi A
Front Endocrinol (Lausanne); 2012; 3():17. PubMed ID: 22645517
[TBL] [Abstract][Full Text] [Related]
15. Is testosterone a friend or a foe of the prostate?
Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
[TBL] [Abstract][Full Text] [Related]
16. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
Morales A
BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
[TBL] [Abstract][Full Text] [Related]
17. Androgen replacement in men undergoing treatment for prostate cancer.
Rhoden EL; Averbeck MA; Teloken PE
J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
[TBL] [Abstract][Full Text] [Related]
18. Testosterone and prostate cancer: revisiting old paradigms.
Isbarn H; Pinthus JH; Marks LS; Montorsi F; Morales A; Morgentaler A; Schulman C
Eur Urol; 2009 Jul; 56(1):48-56. PubMed ID: 19375844
[TBL] [Abstract][Full Text] [Related]
19. Testosterone deficiency syndrome: treatment and cancer risk.
Raynaud JP
J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):96-105. PubMed ID: 19429438
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
